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harboring non-D genotypes were more frequently males 
(p = 0.023), HBeAg-positive (p < 0.001), had higher 
bilirubin (p = 0.014) and viremia (p = 0.034) levels and 
less frequently carried BCP/PC mutations (p < 0.001). 
Non-D genotype patients more often were from Cen-
tral Italy (p = 0.001) and reported risky sexual exposure 
(p = 0.021). Two patients had received vaccination before 
AHB: one harbored genotype F; the other showed a S gene 
mutation. Four patients developed fulminant AHB; muta-
tions were found in 2 of 3 patients who underwent BCP/
PC sequencing. After a 6-month follow-up, only 2 (2.8 %) 
patients developed persistent infection.
Conclusion AHB by non-D genotypes is increasing in 
Italy and is associated with risky sexual exposure. The abil-
ity of some genotypes to cause persistent and/or severe 
infection in Italy warrants larger studies for clarification.
Keywords Acute infection · Epidemiology · Genotypes · 
Hepatitis B · Mutations · Risk factors
Abstract 
Purpose To evaluate the association of hepatitis B virus 
(HBV) genotypes, basal core promoter (BCP)/precore (PC) 
and S gene mutations with the clinical-epidemiological 
characteristics of acute hepatitis B (AHB) in Italy.
Methods During July 2005–January 2007, 103 sympto-
matic AHB patients were enrolled and prospectively fol-
lowed up at 15 national hospitals. HBV genotypes, BCP/
PC and S gene variants were determined by nested-PCR 
and direct sequence analysis.
Results Genotype D, A and F were detected in 49, 45 
and 6 % of patients, respectively. BCP, PC, and BCP 
plus PC variants were found in 3.1, 11.3 and 7.2 % of 
patients, respectively. At enrollment, 68.3 % of patients 
were hepatitis B e antigen (HBeAg)-positive and 31.7 % 
HBeAg-negative. BCP/PC mutations were more com-
mon in HBeAg-negative than in HBeAg-positive patients 
(p < 0.0001). Compared to genotype D patients, those 
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Introduction
Hepatitis B virus (HBV) infection is a major public health 
problem worldwide [1]. More than 240 million people have 
chronic infection and about 600,000 people die every year 
due to the consequences of acute or chronic hepatitis B [2].
The epidemiology of HBV infection in Italy has 
changed substantially over the last few decades and many 
cross-sectional and incidence studies have shown that Italy 
has reached a low level of endemicity [3–6]. Due to imple-
mentation of universal vaccination in 1991, all Italians aged 
0 through 32 years were virtually protected against HBV 
infection in 2013. High-risk sexual behavior, cohabitation 
with a hepatitis B surface antigen (HBsAg)-positive carrier, 
healthcare-related exposures and several beauty treatments 
(including tattooing and piercing) remain the most frequent 
and important risk factors for acute hepatitis B (AHB) 
in Italy [6, 7]. However, it is conceivable that in Italy the 
clinical and epidemiological picture of HBV infection, as 
well as its current level of HBV endemicity, could change 
because of the increasing migration waves from highly 
endemic countries [8, 9].
The HBV genome is characterized by genetic heterogene-
ity. Ten genotypes (A to J) and a number of subtypes have 
been identified so far [10–12]. Interestingly, geographic dis-
tribution, clinical features, disease outcome, and response to 
therapy have been shown to differ according to HBV geno-
types and subtypes in patients with acute and chronic hepa-
titis B (CHB) [1, 10–12]. Besides, different genotypes have 
also a distinct pattern of mutations in some HBV genomic 
regions [PreS and S, basal core promoter (BCP) and precore 
(PC), polymerase], which, in turn, are correlated with the 
clinical characteristics and outcome of both AHB and CHB 
[10, 12]. BCP/PC mutations affecting hepatitis B e antigen 
(HBeAg) production have been widely investigated and have 
been found to be associated with a more severe and progres-
sive form of chronic liver disease in patients with genotype C 
and D and with a fulminant course of AHB [10–13].
Genotype D, which is dominant in the Mediterranean 
basin, has been responsible for the vast majority of cases 
of acute and chronic hepatitis B in Italy for decades [14]. 
However, only a limited number of Italian studies have 
focused on the relevance of different HBV genotypes and 
mutations for the natural history of both AHB and CHB 
[14–20]. Particularly as regards the natural history of AHB, 
so far only three Italian studies have investigated the influ-
ence of HBV genotypes [17–19], and only one has taken 
into consideration the role of genome mutations deemed 
able to influence the clinical disease course [19].
In this prospective study we enrolled a cohort of patients 
with AHB and evaluated the natural course of the infec-
tion by analyzing epidemiological, clinical, serological and 
virological characteristics, including HBV genotype and 
mutations in S gene and BPC/PC regions. This investiga-
tion was also useful to evaluate the impact of immigration 
on the introduction and spread in Italy of unusual and clini-
cally relevant genotypes and mutations [8, 9].
Patients and methods
Participants and setting
This prospective cohort study was conducted at 15 Infec-
tious Disease Units scattered throughout Italy. Between 
July 2005 and January 2007, all consecutive patients with 
symptomatic AHB were enrolled in the study after obtain-
ing written informed consent.
Mandatory inclusion criteria were: high titer [sample/
cutoff (S/CO) ratio ≥10] of immunoglobulin M (IgM) anti-
bodies to hepatitis B core antigen (anti-HBc) [21]; signifi-
cant increase in serum alanine aminotransferase (ALT) levels 
(>10 times the upper limit of normal); acute illness compat-
ible with viral hepatitis. Patients positive for IgM antibodies 
to hepatitis A virus (HAV) or with any other possible cause 
of acute liver damage were excluded. All available medical 
records of patients enrolled in the study were reviewed to 
ascertain the absence of positive HBsAg or anti-HBc tests 
before hospital admission. Immunization records of patients 
who reported previous HBV vaccination were checked to ver-
ify the completeness and correctness of vaccination schedule.
A questionnaire recording information on demographic 
characteristics and risk factors for AHB was administered 
to all patients. All patients underwent clinical, biochemi-
cal and virological assessment at enrolment, then weekly 
during the first month and, in the event of persistence of 
HBsAg in serum, every 3 months thereafter for a total of 
12 months or until the patients withdrew their participation. 
Patients were considered to have recovered from AHB, if 
steady normalization of serum aspartate aminotransferase 
(AST) and ALT levels together with HBsAg clearance 
occurred within 6 months after disease onset. Persistence 
of HBsAg in serum for more than 6 months was consid-
ered evidence of chronic disease evolution. Patients were 
considered to have developed fulminant hepatitis if they 
showed porto-systemic encephalopathy and coagulopa-
thy (reduction in prothrombin activity below 35 %) within 
8 weeks after disease onset.
All patients gave written informed consent before enter-
ing the study. The study was approved by the Ethics Com-
mittee of the Istituto Superiore di Sanità.
Serological tests
All patients were tested for HBsAg, anti-HBc IgM, anti-
HAV IgM, anti-hepatitis C virus (HCV), anti-hepatitis 
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delta virus (HDV) and anti-human immunodeficiency 
virus (HIV) antibodies by commercial immunoassays at 
the enrolling clinical sites. Further serological characteri-
zation of HBV infection was performed at the reference 
laboratory by commercial chemiluminescent assays on 
the ARCHITECT platform (Abbott Diagnostics, Wies-
baden, Germany). Briefly, quantitative methods were 
used for HBsAg (sensitivity of 0.05 IU/mL) and anti-HBs 
(upper quantitation limit of 1000 mIU/mL); total anti-HBc, 
HBeAg, anti-HBe were determined by qualitative assays, 
while anti-HBc IgM was examined by a semiquantitative 
assay.
HBV DNA detection and characterization
HBV DNA was assayed in serum by quantitative PCR 
(Cobas TaqMan HBV Test, Roche Molecular Systems, 
USA) at enrolment, a week later and then—in case of posi-
tivity—until two consecutive samples collected according 
to the follow-up schedule tested negative. HBV genotypes, 
BCP/PC and S gene variants were determined on the first 
HBV DNA-positive sample by nested-PCR in the core/
precore and S regions, followed by direct sequence analysis 
of the amplicons, as previously reported [22, 23].
Statistical analysis
Mann–Whitney test was used for continuous variables to 
assess differences between distributions. Pearson’s Chi-
squared test or Fisher’s exact test was used for comparison 
of frequencies between groups. A p value of 0.05 was con-
sidered significant. All statistical analyses were performed 
using STATA, version 11.2 (StataCorp LP, College Station, 
TX).
Results
General clinical-epidemiological and virological 
characteristics of AHB patients at enrolment
A total of 103 consecutive AHB patients were enrolled 
in the study (Table 1). All patients were symptomatic and 
97 (94.2 %) of them had jaundice. All patients showed 
increased ALT serum levels at least ten times the upper 
limit of normal and had high-titer anti-HBc IgM antibodies 
[average sample/cutoff (S/CO) ratio 32.09 ± 9.24]; all but 
two patients were HBsAg-positive. HBeAg and anti-HBe 
were tested in 101 patients. Of them, 52 (51.5 %) were 
HBeAg-positive/anti-HBe-negative, 29 (28.7 %) HBeAg-
negative/anti-HBe-positive, 17 (16.8 %) HBeAg-positive/
anti-HBe-positive and 3 (2.9 %) HBeAg-negative/anti-
HBe-negative (Table 1; Fig. 1a). High-risk sexual behavior 
and parenteral exposures unrelated to drug use (e.g., noso-
comial exposure, cosmetic treatment with percutaneous 
exposure and cohabitation with a HBsAg-positive carrier) 
were the most frequently reported risk factors (Table 1).
A concomitant infection with HCV, HDV and HIV was 
detected in 4/102 (3.9 %), 1/74 (1.4 %) and 4/74 (5.4 %) 
patients who were tested for these viruses (Table 1).
Serum HBV DNA was examined at disease onset in 
102 patients, of whom 101 tested positive (99 %); one was 
already negative. HBV genotype was determined in 100 of 
the 101 viremic patients: 49 harbored genotype D, 45 geno-
type A and six genotype F (Table 1; Fig. 1b).
BCP/PC variants could be determined in 97 of the 
101 HBV DNA-positive patients. Either BCP (A1762T/
G1764A) or PC (G1896A) variants were found in 3 (3.1 %) 
and 11 (11.3 %) of these patients, respectively; the simulta-
neous presence of BCP and PC mutations was observed in 
7 (7.2 %) patients while the remaining 76 (78.4 %) patients 
harbored BCP/PC wild-type sequences (Table 1; Fig. 1c).
HBeAg/anti-HBe status and BCP/PC mutations were 
tested in 96 patients (Table 2). A significantly higher preva-
lence of BCP/PC variants was observed in HBeAg-negative 
patients compared to HBeAg-positive patients (19/29 or 
65.5 vs 2/67 or 2.9 %; p < 0.001).
The analysis of S gene region mutations was performed 
on the “a” determinant sequences from 91 patients, seven 
of whom (7.7 %) showed mutated sequences, for a total 
of 12 mutations: T126I, S132F, S143L; N131T (n = 2), 
F134Y/N (n = 2 each) and T143 M/S/F.
Clinical-epidemiological and virological characteristics 
of AHB patients at enrolment according to HBV genotype
Data on both infecting genotype and HBe/anti-HBe sta-
tus were available for 99 patients (Tables 2, 3). Patients 
infected with non-D genotypes were more often HBeAg-
positive (66.2 vs 33.8 %) and less frequently HBeAg-neg-
ative (16.1 vs 83.9 %) than patients harboring genotype 
D (Table 2; p < 0.001). The association between HBV 
genotype and HBeAg status was still statistically signifi-
cant, even excluding from the analysis patients with BCP/
PC mutations (20 HBeAg+/7 HBeAg− in genotype D 
patients versus 45 HBeAg+/3 HBeAg− in genotype non-D 
patients, p = 0.030). Patients infected with non-D geno-
types were more often male (p = 0.023), had higher total 
bilirubin level (p = 0.014) and HBV viral load (p = 0.034) 
at enrolment than patients harboring genotype D (Table 3). 
Data on HBV genotype and mutations in the PC and BCP 
regions were available for 97 patients: the overall preva-
lence of BCP/PC mutations was significantly higher in 
patients infected with genotype D than in those harbor-
ing non-D genotypes (19/46 or 41.3 vs 2/51 or 3.9 %; 
p < 0.001) (Table 3).
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Of the seven patients who showed mutated sequences in 
the “a” determinant of the S gene, three patients harbored 
genotype D and carried three mutations: T126I, S132F, 
S143L; while four patients harbored genotype A and 
carried nine mutations: N131T (n = 2), F134Y/N (n = 2 
each) and T143/M/S/F.
The majority of patients (86.4 %) were born and resided 
in Italy, including all those harboring genotype F. Fourteen 
patients were immigrants from eastern Europe (Romania 
[n = 6], Ukraine [4], Bulgaria and Poland) and northern 
Africa (Tunisia and Marocco). No significant difference in 
genotype distribution was detected according to patient’s 
country of birth. Genotype D occurred more frequently in 
patients residing in Southern Italy and Islands as opposed 
to non-D genotypes, which were more frequent in patients 
from Central Italy (p = 0.001) (Table 3).
Interestingly, genotype D was more frequently detected 
in patients who reported intravenous drug use or other par-
enteral exposure, while patients reporting high-risk sexual 
behavior harbored non-D genotypes more often (p = 0.021) 
(Table 3). Overall, more than half of the patients harboring 
non-D genotypes reported high-risk sexual behavior, (4/6 
or 66.7 and 21/45 or 46.7 % of genotype F and A patients, 
respectively). About 10 % of AHB patients reported homo-
bisexual intercourses in the 6 months before the disease 
onset; this exposure was particularly common among 
patients infected with non-D genotypes, notably genotype 
A. However, by comparing only genotype D and genotype 
A patients, the association between genotype A and high-
risk sexual exposure resulted to be only marginally signifi-
cant (p = 0.07).
AHB in previously vaccinated individuals
Two patients enrolled in this study had received a complete 
and well-documented full course of primary HBV vaccina-
tion several years before AHB occurrence, both of whom 
did not undergo pre- or post-vaccination serologic testing. 
The first patient, a 44-year-old man suffering from insulin-
dependent diabetes mellitus since age 22, received HBV vac-
cination about 6 years before AHB presentation. At enrolment 
he was HBsAg-positive, anti-HBs-negative, HBeAg-positive/
anti-HBe-negative and harbored genotype F. The second 
Table 1  Baseline demographic and clinical characteristics in 103 
patients with acute hepatitis B diagnosed at 15 Italian Infectious Dis-
ease Units (2005–2007)
Gender (No. %) 103
 Males 70 (68.0)
 Females 33 (32.0)
Age, median years (range) 37 (16–80)
Geographic area of residence (No. %) 103
 North Italy 23 (22.3)
 Central Italy 35 (34.0)
 Southern Italy and islands 45 (43.7)
Birth country (No. %) 103
 Italy 89 (86.4)
 Abroad 14 (13.6)
Years of schooling (No. %) 89
 ≤8 45 (50.6)
 ≥9 44 (49.4)
Risk factors (No. %)a 103
 Intravenous drug use 6 (5.8)
 Sexual exposureb 40 (38.8)
 Otherc 25 (24.3)
 Undetermined 22 (21.3)
Jaundice (No. %) 97 (94.8)
Hospitalization (No. %) 102 (99.0)
AST (IU/ml), median (range) 1836 (321–5558)
ALT (IU/ml), median (range) 2431 (851–6324)
Total bilirubin (mg/dL), median (range) 15 (1.1–48.9)
Fulminant hepatitis (No. %) 4 (3.9)
Deaths (No. %) 1 (1.0)
Transplantations (No. %) 2 (2.2)
HBV DNA-positive (No. %) 101 (98.0)
HBV DNA (copies/mL), median (range) 110,683 (7–150,000,000)
anti-HBc IgM-positive 103 (100.0)
HBsAg-positive (No. %) 101 (98.0)
HBeAg/anti-HBe status (No. %) 101
 HBeAg+/anti-HBe− 52 (51.5)
 HBeAg−/anti-HBe+ 29 (28.7)
 HBeAg+/anti-HBe+ 17 (16.8)
 HBeAg−/anti-HBe− 3 (2.9)
Coinfection with HCV (No. %) 4 (3.9)
Coinfection with HDV (No. %) 1 (1.4)
Coinfection with HIV (No. %) 4 (5.4)
HBV genotype (No. %) 100
 A 45 (45.0)
 D 49 (49.0)
 F 6 (6.0)
a  Cases may have more than one risk factor
b  Promiscuous sexual activity (more than two sexual partners), and 
unsafe (i.e., no or seldom condom use during occasional sexual inter-
course) homo-bisexual intercourses
c  Cosmetic treatment with percutaneous exposure (piercing, tattoo-
ing, manicure/pedicure, barber shop shaving and acupuncture), living 
with a HBsAg+ carrier, nosocomial exposure, dental treatment
HBV core/precore mutations (No. %) 97
 Precore (PC) 11 (11.3)
 Basal core promoter (BCP) 3 (3.1)
 PC + BCP 7 (7.2)
 Wild type 76 (78.4)
Table 1  continued
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patient, a 19-year-old man with a history of intravenous drug 
use, completed primary vaccination about 15 years before 
AHB presentation. At enrolment, this patient tested HBsAg-
positive, anti-HBs-negative, HBeAg-negative/anti-HBe-posi-
tive. Besides, he harbored genotype D and showed the T126I 
mutation in the “a” determinant of the S gene.
Clinical outcome of AHB
Four AHB patients (3.9 %) developed fulminant hepatitis 
(Table 4). One patient died, two patients underwent trans-
plantation and one other was transferred to a different 
hospital and lost to follow-up. BCP/PC mutations could 
be assessed for three of these four patients: one patient, 
infected with genotype D, showed the simultaneous pres-
ence of BCP and PC variants; another one, infected with 
genotype A, had a BCP mutation; and the last patient, 
harboring genotype D, had wild-type sequences both in 
BCP and PC regions. No coinfection with HCV, HDV and 
HIV was detected in these four patients and none of them 
reported history of chronic liver disease.
A follow-up of at least 6 months, suitable to establish 
AHB recovery or chronic evolution, was available for 72 
(69.9 %) patients (37 harboring genotype D, 29 geno-
type A, five genotype F and one with undetermined geno-
type). Persistence of HBsAg for more than 6 months was 
observed in two of 72 patients (2.8 %; 95 % confidence 
interval 0.3–10.0). Both patients were women and aged 
≥50 years. One of them was infected with genotype A, 
while the other with genotype D (Table 3). In both cases 
BCP/PC wild-type sequences were found. Only one of the 
two patients was tested for anti-HIV antibodies and was 
found to be negative. Among the remaining 70 patients 
who recovered from AHB, 22 (31.4 %) (18 with genotype 
D and four with genotype non-D), 23 (32.9 %) (six with 
genotype D and 16 with genotype non-D) and 25 (35.7 %) 
patients (12 with genotype D and 13 with genotype non-
D) cleared HBsAg within the third month, between 3 and 
6 months, and at the sixth month after enrolment, respec-
tively. Among these patients, HBsAg clearance occurred 
significantly earlier (p = 0.001) in those harboring geno-
type D than in those infected with non-D genotypes.
Thirty-one AHB patients were followed up for less than 
6 months. Twenty-three of these patients withdrew from 
the study within the first month after enrolment; they were 
still HBsAg-positive at the last visit and none of them 
showed evident decrease (>2 logs) in HBsAg levels dur-
ing follow-up. Six patients were followed up for a median 
period of 99.5 days (range 70–115) after enrolment and all 
of them, albeit still positive at the last visit, showed an evi-
dent decrease in HBsAg levels (median decrease 4.5 logs; 
range 4–6 logs) compared to baseline values. Finally, two 
patients, who withdrew from the study after 5 months of 
follow-up, were HBsAg-negative at the last visit.
No significant differences were found at enrolment 
between subjects followed for at least 6 months and those 
lost to follow-up regarding epidemiological, clinical, sero-
logical and virological characteristics (including HBV gen-
otype distribution) (data not shown).
Discussion
In this study, we have provided an overall comprehensive 
description of the clinical, epidemiological and virological 
Fig. 1  Distribution of hepatitis B e antigen (HBeAg)/antibodies to 
hepatitis e antigen (anti-HBe) (a), genotypes (b) and basal core pro-
moter (BCP)/precore (PC) mutations (c) among 103 consecutive 
patients with acute hepatitis B diagnosed at 15 Italian Infectious Dis-
ease Units between July 2005 and January 2007
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Table 2  Distribution of HBV genotypes and precore (PC)/basal core promoter (BCP) region mutations according to HBeAg/anti-HBe status in 
103 patients with acute hepatitis B diagnosed at 15 Italian Infectious Disease Units (2005–2007)
anti-HBe antibodies to hepatitis e antigen, HBeAg hepatitis B e antigen, HBV hepatitis B virus, BCP basal core promoter, PC precore
HBeAg/anti-Hbe status PC and/or BCP (No. 
%)
Wild type (No. %)Total (No. %) Genotype D (No. 
%)
Non-D genotype (No. 
%)
Total (No. 
%)
HBeAg+/anti-HBe− 1 (2.0) 49 (98.0) 50 (100.0) 17 (33.3) 34 (66.6) 51 (100.0)
HBeAg−/anti-HBe+ 18 (66.6) 9 (33.3) 27 (100.0) 24 (82.8) 5 (17.2) 29 (100.0)
HBeAg+/anti-HBe+ 1 (5.9) 16 (94.1) 17 (100.0) 6 (35.3) 11 (64.7) 17 (100.0)
HBeAg−/anti-HB− 1 (50.0) 1 (50.0) 2 (100.0) 2 (100.0) 0 (0.0) 2 (100.0)
HBeAg+ 2 (3.0) 65 (97.0) 67 (100.0) 23 (33.8) 45 (66.2) 68 (100.0)
anti-HBe+ 19 (43.2) 25 (56.8) 44 (100.0) 30 (65.2) 16 (34.8) 46 (100.0)
HBeAg− 19 (65.5) 10 (34.5) 29 (100.0) 26 (83.9) 5 (16.1) 31 (100.0)
anti-HBe− 2 (3.8) 50 (96.2) 52 (100.0) 19 (35.8) 34 (64.2) 53 (100.0)
Table 3  Demographic, clinical, 
biochemical and virological 
characteristics according to 
HBV genotype in patients with 
acute hepatitis B diagnosed at 
15 Italian Infectious Disease 
Units (2005–2007)
a  Cases may have more than 
one risk factor
b  Promiscuous sexual activity 
(more than two sexual partners 
during the previous 6 months), 
and unsafe (i.e., no or seldom 
condom use during occasional 
sexual intercourse) homo-
bisexual intercourses
c  Treatment with percutaneous 
exposure (piercing, tattooing, 
manicure/pedicure, barber shop 
shaving and acupuncture), 
living with a HBsAg+ carrier, 
nosocomial exposure, dental 
treatment
Genotype D Genotype non-D p value
No. (%) No. (%)
No. cases 49 51
Age (years), median (range) 34 (16–80) 37 (21–57) 0.417
Males 28 (57.13) 40 (78.4) 0.023
Geographic area of residence
 North 11 (22.4) 11 (21.6) 0.001
 Central 9 (18.4) 26 (51.0)
 Southern and islands 29 (59.2) 14 (27.4)
Birth country
 Italy 39 (79.6) 47 (92.2) 0.070
 Abroad 10 (20.4) 4 (7.8)
Risk factorsa
 Intravenous drug use 5 (12.5) 1 (2.6) 0.021
 Sexual exposureb 14 (35.0) 25 (64.1)
 Otherc 21 (52.5) 13 (33.3)
 Undetermined 9 (18.4) 12 (23.5)
Chronic evolution 1 (2.7) 1 (2.9) 1.000
Fulminant hepatitis 2 (4.1) 1 (2.0) 0.614
Deaths 1 (2.0) 0 (0.0) 0.490
Transplantations 0 (0.0) 1 (2.0) 1.000
ALT (IU/ml), median (range) 2354 (851–4974) 2436 (1110–6324) 0.268
AST (IU/ml), median (range) 1857.5 (321–5558) 1795 (361–4230) 0.909
Total bilirubin (mg/dL), median (range) 13.65 (1.1–32) 17.1 (1.6–48.9) 0.014
Precore and basal core promoter variations
 Wild type 27 (58.7) 49 (96.1) <0.001
 Mutant strain 19 (41.3) 2 (3.9)
HBV DNA (copies/mL), median (range) 66,761 (7–150 × 106) 332,485 (31–150 × 106) 0.034
HBeAg/anti-HBe status
 HBeAg+/anti-HBe− 17 (33.3) 34 (66.6) <0.001
 HBeAg−/anti-HBe+ 24 (82.8) 5 (17.2)
 HBeAg+/anti-HBe+ 6 (35.3) 11 (64.7)
 HBeAg−/anti-HBe− 2 (100.0) 0 (0.0)
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scenario of AHB in Italy as it appeared many years after 
the occurrence of two events of great epidemiological and 
public health importance, both dated 1991: the introduc-
tion of universal hepatitis B vaccination and the beginning 
of massive immigration to Italy from countries with high 
HBV endemicity.
So far only three Italian studies, performed in Southern 
Italy, have investigated the influence of HBV genotypes 
on the clinical-epidemiological features of AHB [17–19] 
and only one of these studies (which focused on patients 
with severe AHB) has taken into consideration the role of 
genome mutations deemed able to influence the clinical 
disease course [19]. Besides, these studies were conducted 
in one or at most two towns of the same region and enrolled 
about 100–140 patients during nearly 10 years. Thus, in 
these studies only the analysis of separate time intervals of 
recruitment (but with a smaller number of observations in 
each interval) allowed authors to point out major changes 
to the clinical-epidemiological and virological profiles of 
the disease.
A major finding of our study is that more than half 
(51 %) of the observed AHB cases were due to non-D 
genotypes, mainly genotype A and F. Genotype A is preva-
lent in North Europe, the USA, Sub-Saharan and Western 
Africa [10, 11], while genotype F is common in Central 
and South America, although it has already been observed 
in Italy [10, 11, 14, 17, 19, 24]. The prevalence of geno-
type A (45 %) we found in our study was considerably 
higher than that reported in the same range time by Cop-
pola et al. (13.7 %) [17] and by Scalia et al. (27 %) [18]. 
However, these studies were performed in Southern Italy, 
where non-D genotypes, basing on our findings, are less 
frequently detected than genotype D.
Thus, looking at our and other available data [17–20, 
24], it seems that in Italy the frequency of AHB cases due 
to genotype A has increased over time, while AHB cases 
harboring other non-D genotypes have been detected only 
sporadically. This scenario is consistent with the results 
obtained in a large sample of CHB patients in North-East-
ern Italy during the years 2002–2004; among these patients 
the prevalence of genotype D and A was 70.6 and 25 %, 
respectively, while other unusual genotypes (C, E, F, H) 
were detected in very low percentages, mainly in foreign-
ers [14].
In our study, high-risk sexual exposure was the most 
frequently reported risk factor for AHB and it was sig-
nificantly associated with infection by non-D genotypes. 
An association between infection with non-D genotypes 
(particularly genotype A) and high-risk sexual exposure 
was also observed in previous Italian studies [17, 18]. The 
increasing in prevalence of genotype A over time among 
AHB patients and its association with high-risk sexual 
exposure have been well documented by several studies 
in Japan, where genotype C traditionally predominated 
[25–27]. The association between genotype A and high-
risk sexual exposure has also been reported in studies con-
ducted in some Northern European countries, where geno-
type A has always been the most prevalent [28, 29]. The 
above reported change in the molecular epidemiology pat-
tern of AHB over time, well documented in Italy and Japan, 
has been mainly attributed to the immigration phenomenon 
[17, 18, 25, 26]. It has been postulated that genotype A was 
firstly transmitted from infected immigrants to susceptible 
natives by sexual contact, and then it also spread among the 
native population, remaining, however, mainly confined to 
people with at risk sexual behavior [17, 25, 26].
The reasons for the correlation between genotype A and 
sexual transmission have not yet been fully elucidated. 
The high viral load that we and others found in genotype 
A infection [27, 30, 31] increases the HBV concentrations 
in semen and other body fluids of carriers, thus increasing 
the risk of transmission by sexual intercourse. Moreover, 
Japanese studies and our results have shown that genotype 
A infection tends to persist following AHB and this may 
further influence its spread [26, 27, 30, 31]. However, also 
genotype D can be efficiently transmitted through sexual 
contact: about one-third of our AHB patients harboring 
genotype D also reported high-risk sexual behavior. Thus, 
other epidemiological features, in addition to immigra-
tion, may have contributed to the current molecular epide-
miological pattern of AHB in Italy. Indeed, most probably 
this pattern is the consequence of the important changes in 
Table 4  Clinical and laboratory data of four fulminant hepatitis B cases occurred among a cohort of 103 patients with acute hepatitis B diag-
nosed at 15 Italian Infectious Disease Units (2005–2007)
a  Promiscuous sexual activity (more than two sexual partners during the previous 6 months), and unsafe (i.e., no or seldom condom use during 
occasional sexual intercourse) homo-bisexual intercourses
Age Sex Outcome HBV Genotype Precore (PC)/basal core  
promoter (BCP) variants
Risk factor HBeAg/anti-HBe status
46 M Transplantation Undetermined Undetermined Sexual exposurea HBeAg−/anti-HBe+
21 F Transplantation A BCP Undetermined HBeAg+/anti-HBe+
30 F Death D Wild type Undetermined HBeAg−/anti-HBe+
45 M Loss to follow-up D PC, BCP Sexual exposurea Undetermined
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HBV epidemiology that occurred throughout the last dec-
ades in Italy. These changes are mainly due to the univer-
sal vaccination against HBV that has gradually elevated the 
age of the susceptible population. At the time of the study, 
all Italians ≤27 years were virtually protected against HBV. 
The shift in the age of the HBV susceptible population has 
produced a consequent change in the role of different risk 
factors, with a significant reduction in the role of intra-
familial contact and intravenous drug use and an increase 
in the role of unsafe homosexual and heterosexual expo-
sure. This has produced, in turn, an increase in frequency 
of AHB cases due to non-D genotypes, which preferably 
spread among people with high-risk sexual behavior. Stud-
ies based on phylogenetic analysis of genotype A strains 
circulating in Italy could certainly contribute to the defini-
tion of the source and evolution of this genotype.
Data from the present study showed that, in comparison 
with AHB patients infected with genotype D, those infected 
with non-D genotypes were more frequently male and had 
higher total bilirubin level and HBV viral load at enrol-
ment. Besides, they harbored BCP/PC mutant strains less 
frequently and were HBeAg-positive more often. All these 
clinical and virological features have already been reported 
to be distinctive of AHB by genotype A in other countries 
[1, 11, 12, 26, 27, 30, 31], but these characteristics have 
been only incompletely recognized among genotype A (or 
non-D) AHB patients thus far in Italy [17, 18]. The less fre-
quent detection of PC mutations in non-D genotype, most 
notably genotype A, has been ascribed to the instability 
caused by this mutation in the stem-loop structures of the 
pregenome encapsidation signal [27, 32]. This may explain 
the association between non-D genotype and HBsAg posi-
tivity. However, as we and others have observed, this asso-
ciation seems also to be independent from the BCP/PC sta-
tus of patients [14].
Two patients, both harboring genotype D, were HBsAg-
negative at enrollment. Neither of them showed sero-
conversion for HBsAg during the follow-up. Low levels 
of HBsAg in acute hepatitis B have been occasionally 
reported, usually in patients with low replication levels of 
HBV [33]. These two cases had indeed a very low viral 
load (1131 and 7 IU/mL, respectively) on the initial sample 
that tested negative for HBsAg.
In this study a low rate (2.8 %) of AHB chronic evolu-
tion was found. This is in agreement with previous studies 
showing that in immune-competent adults HBV persistence 
after AHB is infrequent [1, 17–19, 34]. Several recent stud-
ies, mainly from Japan, have suggested that high viral load 
and chronic evolution of AHB are more frequent with gen-
otype A infections than with infections due to other geno-
types [11, 12, 26, 27, 30, 31]. Among patients investigated 
by Coppola et al., only three patients developed persistent 
infection and they all harbored genotype D [17]; whereas 
Scalia et al. [18] found that the mean time to HBsAg 
clearance was longer when the proportion of AHB cases 
infected with non-D genotypes increased. We also found 
that HBsAg clearance was significantly delayed in patients 
infected with non-D genotypes who recovered from AHB, 
and this finding is consistent with those of other studies 
[18, 27, 30, 31]. In our cohort two patients developed per-
sistent infection: one with genotype A, the other with geno-
type D, with an essentially similar rate of chronic evolution 
(3.5 vs 2.7 %), but the numbers were too small to enable 
any meaningful analysis.
Fulminant AHB has been reported to be associated with 
non-A genotypes, HBeAg-negative status and, above all, 
the presence of PC e BPC mutations [12, 13]. Although 
there were only four fulminant AHB cases in our study and 
BCP/PC mutations could be assessed in three of them, it is 
intriguing that two patients had BCP/PC mutations. A pre-
exiting HCV chronic infection was identified as the only 
factor associated with a severe or fulminant course of AHB 
among the cohort of Italian patients investigated by Cop-
pola et al. [19]. No coinfection with other hepatitis viruses 
was detected in our four patients with fulminant hepatitis 
and none of them reported history of chronic liver disease.
Two patients developed AHB despite previous vaccina-
tion, although G145R mutation, classically associated with 
vaccine escape, was not detected, suggesting that the pos-
sible selective pressure induced by universal immunization 
has not influenced the emergence and spread of the escape 
variant.
One of the two vaccine recipients suffered from insulin-
dependent diabetes mellitus, a condition already associ-
ated with reduced efficacy of HBV vaccination in adults 
and children [35]. Besides, he was infected with genotype 
F, which has marked sequence differences in the S and P 
gene compared to other genotypes. Since current vaccines 
are based on recombinant HBsAg protein from genotype 
A and D, they may not result in full protective immunity 
towards genotype F infection, even in immune competent, 
fully vaccinated individuals with proper anti-HBs titers 
[36]. The second patient was infected with genotype D, 
yet he showed the T126I mutation in the “a” determinant 
of the S gene. This mutation may have a major impact on 
HBsAg antigenicity and has been associated, especially 
in combination with G145R mutation, with diagnosis fail-
ure (occult infections), poor disease outcome and possible 
escape of vaccine-induced neutralizing antibodies [37, 38]. 
However, since pre- and post-vaccination serological test-
ing was not performed in any of these two patients and both 
of them were anti-HBs-negative at enrolment, no firm con-
clusion can be drawn to explain the reasons for their acute 
infection.
We acknowledge that the sample of AHB patients 
enrolled in our study was not particularly large. It is 
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necessary to consider that, as consequence of universal vac-
cination, the incidence of symptomatic AHB at the time of 
the study was already very low in Italy and the vast major-
ity of cases were aged over 25 years [6]. Nevertheless, our 
study population represented 12 % of all the symptomatic 
cases reported to the Italian surveillance system for acute 
viral hepatitis in the same time range [6] showing similar 
age, sex, geographical area of residence and risk factors as 
those reported by the whole cohort (data not shown). Con-
sequently, our study sample may be considered fairly repre-
sentative of all the AHB cases reported in Italy in the same 
period. Another limitation of our study was that about 30 % 
of patients were lost to follow-up (20 % within the first 
month after the enrolment). We hypothesize that the low 
compliance with follow-up among AHB patients was also 
due to the fact that they were made aware of the favora-
ble disease outcome in most cases. Besides patients, even if 
still positive for HBV markers, usually feel good after hos-
pital discharge and are probably less inclined to adhere to 
follow-up visits.
In conclusion, the results of our study show and confirm 
the increasing spread of non-D genotypes in Italy and the 
substantial changes in the distribution and relevance of the 
various risk factors for AHB. High-risk sexual exposure has 
a major role in HBV acquisition and is significantly asso-
ciated with non-D genotype infection. HBV vaccination 
should be recommended and implemented among adults 
with high-risk sexual behavior.
Further studies on large samples of AHB patients in our 
geographical area are needed to enable a reliable analysis 
of the relationship between HBV genotypes and chronic 
infection, as well as the relationship between BCP/PC 
mutations and disease severity.
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